| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
BTIG analyst Ryan Zimmerman upgrades AVITA Medical (NASDAQ:RCEL) from Sell to Neutral.
Lake Street analyst Frank Takkinen downgrades AVITA Medical (NASDAQ:RCEL) from Buy to Hold and lowers the price target from ...
D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and maintains $14 price target.